company background image
LQDA

Liquidia NasdaqCM:LQDA Stock Report

Last Price

US$5.31

Market Cap

US$341.7m

7D

-6.0%

1Y

95.2%

Updated

15 May, 2022

Data

Company Financials +
LQDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LQDA Stock Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

Liquidia Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Liquidia
Historical stock prices
Current Share PriceUS$5.31
52 Week HighUS$7.78
52 Week LowUS$2.25
Beta0.32
1 Month Change0.57%
3 Month Change-11.50%
1 Year Change95.22%
3 Year Change-45.82%
5 Year Changen/a
Change since IPO-52.16%

Recent News & Updates

May 15
Liquidia Corporation (NASDAQ:LQDA) Just Reported And Analysts Have Been Lifting Their Price Targets

Liquidia Corporation (NASDAQ:LQDA) Just Reported And Analysts Have Been Lifting Their Price Targets

Shareholders might have noticed that Liquidia Corporation ( NASDAQ:LQDA ) filed its quarterly result this time last...

Shareholder Returns

LQDAUS PharmaceuticalsUS Market
7D-6.0%0.2%-2.5%
1Y95.2%9.9%-10.4%

Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: LQDA exceeded the US Market which returned -10.4% over the past year.

Price Volatility

Is LQDA's price volatile compared to industry and market?
LQDA volatility
LQDA Average Weekly Movement12.5%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: LQDA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: LQDA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200452Roger Jeffshttps://www.liquidia.com

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States.

Liquidia Fundamentals Summary

How do Liquidia's earnings and revenue compare to its market cap?
LQDA fundamental statistics
Market CapUS$341.67m
Earnings (TTM)-US$41.34m
Revenue (TTM)US$13.26m

25.8x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LQDA income statement (TTM)
RevenueUS$13.26m
Cost of RevenueUS$3.02m
Gross ProfitUS$10.24m
Other ExpensesUS$51.58m
Earnings-US$41.34m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.64
Gross Margin77.21%
Net Profit Margin-311.72%
Debt/Equity Ratio35.2%

How did LQDA perform over the long term?

See historical performance and comparison

Valuation

Is Liquidia undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: LQDA ($5.31) is trading below our estimate of fair value ($85.26)

Significantly Below Fair Value: LQDA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: LQDA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: LQDA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LQDA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LQDA is overvalued based on its PB Ratio (6.2x) compared to the US Pharmaceuticals industry average (1.7x).


Future Growth

How is Liquidia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


69.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LQDA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LQDA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LQDA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LQDA's revenue (50.1% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: LQDA's revenue (50.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LQDA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Liquidia performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-4.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LQDA is currently unprofitable.

Growing Profit Margin: LQDA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LQDA is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.

Accelerating Growth: Unable to compare LQDA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LQDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.5%).


Return on Equity

High ROE: LQDA has a negative Return on Equity (-74.63%), as it is currently unprofitable.


Financial Health

How is Liquidia's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LQDA's short term assets ($62.0M) exceed its short term liabilities ($8.0M).

Long Term Liabilities: LQDA's short term assets ($62.0M) exceed its long term liabilities ($30.2M).


Debt to Equity History and Analysis

Debt Level: LQDA has more cash than its total debt.

Reducing Debt: LQDA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LQDA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LQDA has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 13% each year.


Dividend

What is Liquidia current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LQDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LQDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LQDA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LQDA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LQDA has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Roger Jeffs (59 yo)

0.33

Tenure

US$93,251

Compensation

Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He...


Leadership Team

Experienced Management: LQDA's management team is considered experienced (2 years average tenure).


Board Members

Experienced Board: LQDA's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LQDA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.


Top Shareholders

Company Information

Liquidia Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Liquidia Corporation
  • Ticker: LQDA
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$341.669m
  • Shares outstanding: 64.34m
  • Website: https://www.liquidia.com

Number of Employees


Location

  • Liquidia Corporation
  • 419 Davis Drive
  • Suite 100
  • Morrisville
  • North Carolina
  • 27560
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.